Johnson & Johnson - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 423 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Johnson & Johnson - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Johnson & Johnson - Product Pipeline Review - 2016', provides an overview of the Johnson & Johnson's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson
- The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Johnson & Johnson's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Johnson & Johnson's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Johnson & Johnson's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Johnson & Johnson's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Johnson & Johnson Snapshot 8
Johnson & Johnson Overview 8
Key Information 8
Key Facts 8
Johnson & Johnson - Research and Development Overview 9
Key Therapeutic Areas 9
Johnson & Johnson - Pipeline Review 19
Pipeline Products by Stage of Development 19
Pipeline Products - Monotherapy 20
Pipeline Products - Combination Treatment Modalities 21
Pipeline Products - Partnered Products 22
Pipeline Products - Out-Licensed Products 25
Johnson & Johnson - Pipeline Products Glance 27
Johnson & Johnson - Late Stage Pipeline Products 27
Johnson & Johnson - Clinical Stage Pipeline Products 30
Johnson & Johnson - Early Stage Pipeline Products 34
Johnson & Johnson - Unknown Stage Pipeline Products 39
Johnson & Johnson - Drug Profiles 40
(canagliflozin + metformin hydrochloride XR) 40
bedaquiline fumarate 41
daratumumab 44
ustekinumab 48
bortezomib 51
golimumab 57
tipifarnib 60
(cobicistat + darunavir + emtricitabine + tenofovir alafenamide) 63
(naproxen sodium + sumatriptan succinate) 65
abiraterone acetate 67
canagliflozin 70
esketamine hydrochloride 72
fulranumab 75
guselkumab 78
imetelstat sodium 81
infliximab 84
JNJ-56021927 86
rivaroxaban 88
sirukumab 94
tapentadol hydrochloride IR 97
trabectedin 99
JNJ-54861911 105
(AL-335 + odalasvir + simeprevir) 107
AL-335 108
ALS-8176 109
Cell Therapy for HIV-1 Infection 110
CNTO-3157 111
CNTO-6785 112
erdafitinib 114
JNJ-39393406 116
JNJ-40411813 118
JNJ-42039556 119
JNJ-42847922 121
JNJ-49095397 123
JNJ-53718678 125
JNJ-56022473 126
JNJ-56914845 127
JNJ-872 129
odalasvir 131
ORM-12741 132
quisinostat hydrochloride 133
rilpivirine 135
siltuximab 138
sovaprevir 141
TMC-310911 143
toreforant tartrate 144
CNTO-2476 146
COVA-322 147
telaprevir 148
Vaccine for Prostate Cancer 152
ACH-3422 155
AL-794 156
ALS-8112 157
CNTO-7160 158
EVT-100 Series 159
EVT-103 160
JNJ-18038683 162
JNJ-38877618 164
JNJ-42721458 165
JNJ-47910382 166
JNJ-49122944 167
JNJ-54175446 168
JNJ-55375515 169
JNJ-55920839 170
JNJ-56136379 171
JNJ-61610588 172
JNJ-64052781 173
JNJ-757 174
JNJ-809 176
NVR-3778 177
RV-1162 179
RV-1729 180
TOP-1288 181
Small Molecules for Rhinovirus Infections 182
Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections 183
AL-516 184
CNTO-530 185
COVA-208 186
COVA-420 187
COVA-493 188
COVA-494 189
DiTU 190
flubendazole 192
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction 194
JNJ-26070109 195
JNJ-26993135 196
JNJ-28307474 197
JNJ-28312141 198
JNJ-28610244 199
JNJ-31020028 200
JNJ-35815208 201
JNJ-375 202
JNJ-39729209 203
JNJ-39933673 204
JNJ-40279486 205
JNJ-40413269 206
JNJ-41477670 207
JNJ-42314415 208
JNJ-42905343 209
JNJ-46778212 210
JNJ-47965567 211
JNJ-5234801 212
JNJ-54416076 213
Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis 214
Monoclonal Antibody for Autoimmune Diseases 215
Nucleozin 216
Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases 217
Recombinant Protein-1 for Undisclosed Indication 218
Recombinant Protein-2 for Undisclosed Indication 219
Recombinant Proteins for Inflammatory and Autoimmune Diseases 220
RV-1088 221
S-961 222
Small Molecule to Inhibit Capsid Protein for Hepatitis B 223
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia 224
Small Molecule to Inhibit FLT3 for AML 225
Small Molecule to Inhibit PDE10A for Schizophrenia 226
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity 227
Small Molecules to Antagonize P2X7 for Central Nervous System 228
Small Molecules to Inhibit FMS for Rheumatoid Arthritis 229
Stem Cell Therapy for Type 1 and Type 2 Diabetes 230
VE-202 231
ALS-2135 232
Cellular Immunotherapy for Solid Tumors 233
Drugs for Cancer 234
Drugs for Prostate Cancer 235
influenza vaccine 236
LCTA-949 237
Peptides to Inhibit Ion Channel for Chronic Pain 238
Recombinant Protein for Inflammatory Bowel Diseases 239
Small Molecule to Inhibit cccDNA for Hepatitis B 240
Small Molecule to Inhibit Kinase for Autoimmune Diseases 241
Small Molecules for Central Nervous System Disorders 242
Small Molecules for Hepatitis B 243
Small Molecules for Lymphoma 244
Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer 245
Small Molecules to Antagonize CCR2 for Type II Diabetes 246
Small Molecules to Block Cav2.2 Channel for Chronic Pain 247
TMC-207 Back Up 248
VX-353 249
Biologics for Undisclosed Indication 250
JNJ-40346527 251
RV-6153 253
Johnson & Johnson - Pipeline Analysis 254
Johnson & Johnson - Pipeline Products by Target 254
Johnson & Johnson - Pipeline Products by Route of Administration 262
Johnson & Johnson - Pipeline Products by Molecule Type 263
Johnson & Johnson - Pipeline Products by Mechanism of Action 264
Johnson & Johnson - Recent Pipeline Updates 275
Johnson & Johnson - Dormant Projects 381
Johnson & Johnson - Discontinued Pipeline Products 386
Discontinued Pipeline Product Profiles 386
Johnson & Johnson - Company Statement 389
Johnson & Johnson - Locations And Subsidiaries 391
Head Office 391
Other Locations & Subsidiaries 391
Appendix 412
Methodology 412
Coverage 412
Secondary Research 412
Primary Research 412
Expert Panel Validation 412
Contact Us 412
Disclaimer 413

List of Tables

Johnson & Johnson, Key Information 18
Johnson & Johnson, Key Facts 18
Johnson & Johnson - Pipeline by Indication, 2016 20
Johnson & Johnson - Pipeline by Stage of Development, 2016 29
Johnson & Johnson - Monotherapy Products in Pipeline, 2016 30
Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016 31
Johnson & Johnson - Partnered Products in Pipeline, 2016 32
Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2016 33
Johnson & Johnson - Out-Licensed Products in Pipeline, 2016 35
Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2016 36
Johnson & Johnson - Pre-Registration, 2016 37
Johnson & Johnson - Filing rejected/Withdrawn, 2016 38
Johnson & Johnson - Phase III, 2016 39
Johnson & Johnson - Phase II, 2016 40
Johnson & Johnson - Phase I, 2016 42
Johnson & Johnson - IND/CTA Filed, 2016 44
Johnson & Johnson - Preclinical, 2016 45
Johnson & Johnson - Discovery, 2016 48
Johnson & Johnson - Unknown, 2016 49
Johnson & Johnson - Pipeline by Target, 2016 264
Johnson & Johnson - Pipeline by Route of Administration, 2016 272
Johnson & Johnson - Pipeline by Molecule Type, 2016 273
Johnson & Johnson - Pipeline Products by Mechanism of Action, 2016 274
Johnson & Johnson - Recent Pipeline Updates, 2016 285
Johnson & Johnson - Dormant Developmental Projects,2016 391
Johnson & Johnson - Discontinued Pipeline Products, 2016 396
Johnson & Johnson, Subsidiaries 401